CAR-T Cell Therapy Market is expected to reach US$ 20.4 billion by 2033 | Major Companies - Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb company.

Market Size and Growth:

The Global CAR-T Cell Therapy Market Size reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/car-t-cell-therapy-market?sz

The CAR-T Cell Therapy Market refers to the global industry focused on developing, producing, and commercializing chimeric antigen receptor T-cell therapies used to treat cancer. It involves genetic modification of a patient's T-cells to recognize and destroy malignant cells. The market includes research, clinical trials, manufacturing, regulatory approvals, and commercialization of personalized, targeted immunotherapies.

United States: Recent Developments of CAR-T Cell Therapy Market

✅ In October 2025, Kincell Bio partnered with Moonlight Bio to advance Moonlight's lead T-cell therapy program into clinical trials.​

✅ In October 2025, Citius Oncology signed an exclusive agreement with EVERSANA and a distribution deal with McKesson for the commercialization of LYMPHIR, an FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma.​

✅ In December 2025, Kite Pharma reported encouraging Phase 1 results for next-generation bicistronic CAR T-cell therapies in relapsed/refractory B-cell lymphoma, showing durable remissions at higher doses with manageable safety.​

Europe: Recent Developments of CAR-T Cell Therapy Market

✅ In November 2025, NHS England announced availability of obecabtagene autoleucel (Aucatzyl), a UK-developed CAR T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, noted for lower toxicity.​

✅ In November 2025, the European Medicines Agency recommended approval of Waskyra, a gene therapy related to cell therapies for Wiskott-Aldrich syndrome, advancing options for immune disorders.​

✅ In November 2025, Captain T Cell secured additional funding totaling €20 million to advance its TCR-T cell therapy CTC127 into Phase I trials for MAGE-A4-positive solid tumors across German centers.​

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/car-t-cell-therapy-market?sz

Regulatory Approvals & Policy changes (2025):

✅ June 2025 - FDA removes REMS requirement for autologous CAR-T therapies. The FDA announced it was eliminating the Risk Evaluation and Mitigation Strategies (REMS) that previously applied to currently approved autologous CAR-T products (e.g., CD19- and BCMA-directed therapies), changing how safety is managed and expected to ease access.

✅ December 2025 - FDA approves lisocabtagene maraleucel (Breyanzi) for relapsed/refractory marginal zone lymphoma (MZL). (U.S. approval announced December 4, 2025.) This expands a CD19-directed CAR-T indication.

Major Mergers & Acquisitions in (2025):

✅ January 2025 - Roche completes acquisition of Poseida Therapeutics. Roche finalized the Poseida transaction (deal announced in Nov 2024; completion activity occurred in early January 2025) to add allogeneic CAR-T and related cell-therapy capabilities.

✅ June 2025 (deal announced) / August 2025 (closing activity) - AbbVie announced agreement to acquire Capstan Therapeutics (up to $2.1B). The definitive agreement was announced June 30, 2025 (Capstan develops in-vivo / LNP-delivered CAR-T approaches); completion/close-related filings followed later.

✅ August 2025 - Gilead's Kite Pharma announced (or agreed) to acquire Interius BioTherapeutics. The deal is aimed at advancing in-vivo CAR-T delivery platforms (announced August 21, 2025).

Major Players:

Key companies in the CAR-T Cell Therapy market include:

Novartis AG
Gilead Sciences, Inc.
Bristol Myers Squibb company
Johnson & Johnson
Autolus Therapeutics
Pfizer Inc.
BioNTech SE.
Merck KGaA
Allogene Therapeutics
Atara Biotherapeutics, Inc.

Segments Covered in the CAR-T Cell Therapy Market:

By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy.

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta.

By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others.

By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others.

Regional Analysis for CAR-T Cell Therapy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=car-t-cell-therapy-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, CAR-T Cell Therapy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global CAR-T Cell Therapy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global CAR-T Cell Therapy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the CAR-T Cell Therapy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of CAR-T Cell Therapy market?

➠ Who are the global key manufacturers of the CAR-T Cell Therapy Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the CAR-T Cell Therapy market opportunities and threats faced by the vendors in the global CAR-T Cell Therapy Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the CAR-T Cell Therapy market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.